Investor Relations
MOLOGEN is a technology leader in the field of DNA-based therapies. We are developing active cancer immuno-therapies with blockbuster market potential as well as vaccines against severe infectious diseases.
The Paul-Ehrlich Institute has granted approval for a phase I clinical study of a gene therapy with MGN1404 for the treatment of melanomas. The study is entitled "Phase I trial of TNF-alpha expressing MIDGE-vector non-viral gene transfer in skin metastases of melanoma." The study will be conducted by collaborative partners Charité... [more]
Annual Report 2012
Interim Report 3rd Quarter 2012
Half-Year-Report 2012
Interim Report 1st Quarter 2012
March 21, 2013
Annual Financial Statements and Annual Report 2012
May 15, 2013
Quarterly Report as of March, 2013
May 15, 2013
German Biotechnology Days 2013
Presentation of Dr. Anne Endmann on the "Development of a
DNA vaccine against hepatitis B (MGN1333)", Stuttgart, Germany
May 15, 2013 - May 18, 2013
ASGCT 16th Annual Meeting 2013
Scientific Congress, Salt Lake City, UT (USA)
November 22, Thomson Reuters
Video recording
Company presentation (35')
Interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG
Share Price
Contact:
Jörg Petraß
Chief Financial Officer
Tel.: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
[email protected]
Related Links